Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
XERIS PHARMACEUTICALS INC (XERS)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| | 10-K | 10-K | 10-K | 10-K | S-1 |
| Revenues | 100.0% | 100.0% | | 100.0% | 100.0% |
| Cost of goods sold | 46.3% | 98.5% | | 25.0% | 15.1% |
| Gross profit | 53.7% | 1.5% | | 75.0% | 84.9% |
| Selling, general and administrative | 365.8% | 3875.9% | | 50093.8% | |
| Research and development | 103.8% | 3714.7% | | 126037.5% | 19317.0% |
| General and administrative | | | | | 7660.4% |
| EBITDA | -407.2% | -7455.6% | | -165025.0% | -24745.3% |
| Depreciation | 7.3% | 66.3% | | 1406.3% | 218.9% |
| EBIT | -414.5% | -7521.8% | | -166431.3% | -24964.2% |
| Pre-tax income | -452.2% | -7718.5% | | -165962.5% | -24922.6% |
| Income taxes | 0.5% | 28.1% | | 0.0% | 0.0% |
| Net income | -452.7% | -7746.7% | | -165962.5% | -24922.6% |
|